Edwards Lifesciences Corporation $EW Shares Bought by Comprehensive Financial Consultants Institutional Inc.

Comprehensive Financial Consultants Institutional Inc. raised its position in Edwards Lifesciences Corporation (NYSE:EW) by 13.1% during the 2nd quarter, according to its most recent filing with the SEC. The firm owned 30,455 shares of the medical research company’s stock after buying an additional 3,523 shares during the quarter. Comprehensive Financial Consultants Institutional Inc.’s holdings in Edwards Lifesciences were worth $2,382,000 as of its most recent filing with the SEC.

Other institutional investors also recently bought and sold shares of the company. Allspring Global Investments Holdings LLC increased its stake in Edwards Lifesciences by 0.5% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 30,195 shares of the medical research company’s stock valued at $2,170,000 after buying an additional 145 shares during the period. Pacific Capital Partners Ltd acquired a new position in Edwards Lifesciences in the 2nd quarter valued at $1,760,000. Czech National Bank increased its stake in Edwards Lifesciences by 5.8% in the 2nd quarter. Czech National Bank now owns 143,385 shares of the medical research company’s stock valued at $11,214,000 after buying an additional 7,917 shares during the period. Wealth Enhancement Advisory Services LLC grew its stake in shares of Edwards Lifesciences by 13.5% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 77,016 shares of the medical research company’s stock worth $5,582,000 after purchasing an additional 9,188 shares during the period. Finally, Dynamic Advisor Solutions LLC grew its stake in shares of Edwards Lifesciences by 2.4% during the 1st quarter. Dynamic Advisor Solutions LLC now owns 15,506 shares of the medical research company’s stock worth $1,124,000 after purchasing an additional 370 shares during the period. 79.46% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms have recently weighed in on EW. Stifel Nicolaus set a $85.00 price target on shares of Edwards Lifesciences and gave the stock a “buy” rating in a research note on Monday, September 22nd. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Edwards Lifesciences in a research note on Saturday, September 27th. JPMorgan Chase & Co. upped their price target on shares of Edwards Lifesciences from $80.00 to $85.00 and gave the stock a “neutral” rating in a research note on Friday, July 25th. BTIG Research raised shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating and set a $100.00 price target on the stock in a research note on Tuesday, July 29th. Finally, Evercore ISI upped their price target on shares of Edwards Lifesciences from $77.00 to $80.00 and gave the stock an “in-line” rating in a research note on Friday, July 25th. Three analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Edwards Lifesciences has an average rating of “Moderate Buy” and a consensus price target of $86.61.

Edwards Lifesciences Price Performance

Edwards Lifesciences stock opened at $77.03 on Monday. Edwards Lifesciences Corporation has a 52 week low of $64.00 and a 52 week high of $83.00. The company has a quick ratio of 3.87, a current ratio of 4.68 and a debt-to-equity ratio of 0.06. The firm’s 50-day simple moving average is $78.50 and its 200 day simple moving average is $76.01. The firm has a market capitalization of $45.22 billion, a PE ratio of 11.08, a P/E/G ratio of 3.71 and a beta of 1.05.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Thursday, July 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.62 by $0.05. The company had revenue of $1.53 billion for the quarter, compared to analyst estimates of $1.49 billion. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The firm’s quarterly revenue was up 11.9% on a year-over-year basis. During the same period in the prior year, the firm earned $0.70 EPS. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. On average, equities research analysts predict that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 4,114 shares of the company’s stock in a transaction dated Monday, July 28th. The shares were sold at an average price of $79.46, for a total value of $326,898.44. Following the transaction, the vice president directly owned 22,002 shares in the company, valued at approximately $1,748,278.92. This represents a 15.75% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Larry L. Wood sold 8,950 shares of the company’s stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $78.06, for a total transaction of $698,637.00. Following the completion of the transaction, the insider owned 206,900 shares in the company, valued at approximately $16,150,614. This trade represents a 4.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.34% of the stock is currently owned by corporate insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.